Most antibiotics work by attacking a handful of essential structures and processes inside bacterial cells that either do not exist in human cells or differ enough that the drug can distinguish friend from foe. The classic targets fall into five broad categories: cell wall assembly, the cell membrane, the ribosome (the cell’s protein-making machinery), nucleic acid synthesis (DNA and RNA), and key metabolic pathways. Understanding what each class of antibiotic actually hits inside the bacterium helps explain why certain drugs work against certain infections, why resistance keeps evolving, and why developing new antibiotics is so difficult.
Cell Wall Assembly
The bacterial cell wall is made of a mesh-like material called peptidoglycan, and it is arguably the single most exploited antibiotic target in clinical medicine. Human cells lack peptidoglycan entirely, which makes the wall an appealing bullseye: drugs that interfere with it can devastate bacteria while leaving your own cells largely unharmed.1PubMed Central. Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens
Beta-lactams, the family that includes penicillin, amoxicillin, and the cephalosporins, are the best-known drugs in this category. They work by binding to enzymes called penicillin-binding proteins (PBPs), which are responsible for cross-linking the strands of peptidoglycan into a sturdy lattice. When those enzymes are blocked, the wall weakens and the bacterium bursts open under its own internal pressure. Glycopeptide antibiotics like vancomycin take a different approach: instead of binding the enzyme, they latch onto the building-block molecules themselves, sequestering the precursor pieces so the wall can never be properly assembled.2PubMed Central. Targeting Bacterial Cell Wall Synthesis: Structural Insights and Emerging Therapeutic Strategies Other drugs hit earlier steps in the pathway. Fosfomycin blocks an enzyme called MurA that kicks off production of the wall’s building blocks, while cycloserine interferes with enzymes that prepare the amino acid components before they are even linked together.3Biochemical Pharmacology. Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?
The reason so many different antibiotics target different steps of this one pathway is partly historical luck and partly biology: building a cell wall requires a long chain of enzymatic reactions, and each link in that chain is a potential point of attack. That diversity has been a gift in clinical medicine, because when resistance closes one door in the pathway, a drug hitting a different step can sometimes still get through.
The Cell Membrane
Where the cell wall is a rigid scaffold, the cell membrane is the thin lipid barrier just beneath it that controls what enters and exits the cell. A few antibiotic classes target the membrane directly, and they tend to be reserved for the most dangerous drug-resistant infections because of their potency and, in some cases, their toxicity to the patient.
Polymyxins, including colistin, are the leading example for Gram-negative bacteria. They bind to a lipid component called lipopolysaccharide (LPS) in the outer membrane of organisms like Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa. Once attached, polymyxins disrupt the membrane’s structure, ultimately punching holes that kill the cell. Recent research has refined the picture: energy-dependent disruption of the outer membrane is not itself lethal but opens the door for the drug to reach the inner membrane, which it then permeabilizes in an energy-independent way, and that step is what actually kills the bacterium.4PubMed Central. Polymyxin B lethality requires energy-dependent outer membrane disruption
On the Gram-positive side, the lipopeptide daptomycin works differently. It requires a membrane lipid called phosphatidylglycerol and is used against drug-resistant Gram-positive pathogens such as MRSA and vancomycin-resistant enterococci. Despite their distinct molecular targets, both polymyxins and daptomycin cause membrane disruption and are potently bactericidal.5PubMed Central. Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort Clinicians usually hold these drugs in reserve, deploying them only when other options fail, partly to slow resistance and partly because membrane-targeting antibiotics can be rough on the kidneys and nerves.
The Ribosome
Roughly half of all antibiotic classes in clinical use target the bacterial ribosome, the molecular machine that reads genetic instructions and assembles proteins accordingly. Bacterial ribosomes are smaller and structurally distinct from the ribosomes in human cells, and that difference is what makes them a viable drug target. Early work on erythromycin, for instance, showed that the drug binds tightly to bacterial ribosomes but cannot bind to mammalian ribosomes at all, explaining why it kills bacteria without poisoning the patient.6Biochemical Pharmacology. Biochemical basis for the selective toxicity of erythromycin
The ribosome has two functional halves, and antibiotics can be loosely grouped by which half they hit. Drugs that target the smaller subunit include aminoglycosides (like gentamicin) and tetracyclines. Aminoglycosides cause the ribosome to misread the genetic code, inserting wrong amino acids into proteins and producing garbage that poisons the cell. Tetracyclines physically block the slot where new amino acids are delivered, stalling protein production altogether.
Drugs that target the larger subunit include macrolides (like azithromycin), lincosamides (like clindamycin), oxazolidinones (like linezolid), and chloramphenicol. These generally jam the tunnel through which the growing protein chain exits the ribosome, or they interfere with the chemical step that links amino acids together.7PubMed Central. Mechanistic Insights into Clinically Relevant Ribosome-Targeting Antibiotics The specifics vary by drug class, but the result is the same: the bacterium cannot make the proteins it needs to survive.
DNA Replication
Bacteria need to copy their DNA to divide, and the enzymes that manage that process are another major antibiotic target. The fluoroquinolones, a family that includes ciprofloxacin and levofloxacin, go after two related enzymes: DNA gyrase and topoisomerase IV. Both enzymes work by temporarily cutting DNA strands, rearranging the topology, and then resealing the break. Fluoroquinolones corrupt this process by stabilizing the cut state, trapping the enzyme bound to broken DNA. The bacterium is then stuck with unresolved DNA breaks, which are lethal.8PubMed Central. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance
Structural studies have shown that fluoroquinolones wedge themselves into the enzyme-DNA complex through a bridging interaction involving a metal ion, and this bridge is a key contact point across multiple bacterial species.9PubMed Central. Target-Mediated Fluoroquinolone Resistance in Neisseria gonorrhoeae: Actions of Ciprofloxacin against Gyrase and Topoisomerase IV The drug does not just freeze the enzyme in place; it actively promotes additional DNA cleavage, generating more breaks than the cell can handle.10Journal of Biological Chemistry. Fluoroquinolone-Gyrase-DNA Complexes: TWO MODES OF DRUG BINDING Because gyrase and topoisomerase IV are essential in virtually all bacteria, fluoroquinolones are used against a wide range of infections, from urinary tract infections to pneumonia.
RNA Transcription
Copying DNA into RNA is the first step in gene expression, and one of the most clinically important drugs that blocks this step is rifampicin. It works by binding to bacterial RNA polymerase, the enzyme that reads DNA and builds an RNA strand from it. Structural studies have pinpointed the mechanism: rifampicin sits in a pocket that physically blocks the path of the growing RNA strand when it is only two or three building blocks long, stalling transcription at its earliest stage.11PubMed. Structural mechanism for rifampicin inhibition of bacterial rna polymerase The drug does not prevent RNA polymerase from starting its job; it prevents it from getting anywhere.
Rifampicin is one of the most potent and broad-spectrum antibiotics ever developed, but it is best known for its role in treating tuberculosis. Because Mycobacterium tuberculosis rapidly develops resistance to rifampicin when it is used alone, the drug is always given in combination with other agents. Resistance typically arises from mutations in the binding pocket of RNA polymerase that weaken the drug’s grip, which is why monotherapy is essentially never an option.
Folate Metabolism
Not all antibiotics physically destroy a structure inside the bacterium. Some starve it by cutting off essential chemical supplies. The best example involves the folate pathway, which bacteria use to make tetrahydrofolate (THF), a molecule they need for building DNA. Humans get folate from food; many bacteria have to synthesize it from scratch. That difference makes the folate pathway a target that is naturally selective for bacteria.
Sulfamethoxazole blocks an early step in the pathway, preventing production of a precursor called dihydropteroate. Trimethoprim blocks a later step, preventing conversion of dihydrofolate into the active THF form. The two drugs are often prescribed together as a fixed combination known as co-trimoxazole, and the conventional explanation for their synergy was that hitting two sequential steps in the same pathway creates a double blockade. Recent work has demonstrated that the synergy is actually more potent and more complex than that simple model would predict, with each drug amplifying the other’s effect through feedback loops within the cell’s metabolism.12PubMed Central. Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole
Energy Production and Mycobacteria-Specific Targets
Tuberculosis treatment has pushed researchers to look beyond the classic five target categories. M. tuberculosis is protected by an unusually thick, waxy cell envelope rich in long-chain fatty acids called mycolic acids. There are many enzymes involved in building mycolic acids, and each one is a potential drug target. Isoniazid, a cornerstone of TB therapy, works by inhibiting an enzyme called InhA in that pathway.13PubMed Central. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics
More recently, bedaquiline opened an entirely new class of antibiotic targets by going after the bacterium’s energy supply. It inhibits ATP synthase, the enzyme that generates ATP, the cell’s universal energy currency. Blocking ATP production is effective against M. tuberculosis partly because the organism relies heavily on oxidative phosphorylation, even during dormant or slow-growing states when many other antibiotics fail.14PubMed Central. Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline Bedaquiline was the first new TB drug approved in decades, and it signaled that energy metabolism is a viable and underexplored frontier for antibiotic development.
Prodrugs That Hit Multiple Targets at Once
Some antibiotics do not neatly fit into a single target category because they are prodrugs: inactive molecules that bacteria themselves activate, unleashing reactive fragments that damage multiple targets simultaneously. Nitrofurantoin, widely prescribed for urinary tract infections, is a classic example. Inside the bacterial cell, enzymes called nitroreductases reduce the drug’s nitro group, generating highly reactive intermediates like free radicals and hydroxylamine. These reactive species attack ribosomes, damage DNA and RNA, and interfere with other enzymes in a nonspecific barrage that makes it difficult for bacteria to develop resistance through any single mutation.15PubMed Central. Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales – Section: Mechanisms of Nitrofurantoin Action
Metronidazole and the nitroimidazole family work by a similar logic: anaerobic bacteria reduce the drug internally, and the activated form damages DNA. This multi-hit approach is one reason nitrofurantoin has stayed effective against common bladder infections for decades while resistance to single-target antibiotics like ciprofloxacin has climbed steadily. When your drug wrecks several targets at once, the bacterium would need to simultaneously develop resistance on multiple fronts, which is far less likely.
Why Bacteria Are Not Defenseless
Knowing the targets only tells half the story. Bacteria fight back, and they often do so by modifying the very targets that antibiotics attack. In MRSA, for example, the bacterium acquires a gene encoding an alternative penicillin-binding protein called PBP2a. This replacement enzyme can still cross-link the cell wall even when beta-lactam antibiotics are present, because its active site resists the drug’s binding in two ways: the rate at which the drug can chemically attach to the enzyme drops by several thousand-fold, and the initial weak-binding step that precedes that attachment is also impaired.16PubMed Central. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function17Journal of Biological Chemistry. The Basis for Resistance to β-Lactam Antibiotics by Penicillin-binding Protein 2a of Methicillin-resistant Staphylococcus aureus The result is broad resistance to virtually every beta-lactam on the market.
At the ribosome level, bacteria deploy enzymes that chemically modify the ribosomal RNA where antibiotics bind. One group of these enzymes can collectively render seven different classes of ribosome-targeting antibiotics ineffective, which is an alarming breadth of cross-resistance stemming from a single type of change.18PubMed Central. Ribosome-targeting antibiotics and resistance via ribosomal RNA methylation A particularly well-studied case involves an enzyme called Cfr, which modifies a single highly conserved spot on the ribosomal RNA, blocking drugs from multiple classes simultaneously.19Nucleic Acids Research. Antibiotic resistance evolved via inactivation of a ribosomal RNA methylating enzyme
Beyond target modification, Gram-negative bacteria have an extra trick: their double membrane and efflux pumps. The outer membrane acts as a physical barrier that keeps many antibiotics out in the first place, while efflux pumps actively recognize drugs that do get in and eject them back out before they can reach their target.20PubMed Central. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria Some of these pumps are broad-specificity, meaning they can expel structurally unrelated drugs, making the cell resistant to several antibiotic classes at once. Research into the chemical properties that help a drug avoid efflux suggests that getting past these pumps is just as important as hitting the right target.21npj Antimicrobials and Resistance. Multidrug efflux in Gram-negative bacteria: structural modifications in active compounds leading to efflux pump avoidance The interplay between reduced influx through porins and increased efflux through pumps is a major reason Gram-negative infections are generally harder to treat than Gram-positive ones.22PubMed Central. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance
Bacteria can also amplify their resistance genes, producing extra copies that flood the cell with resistance proteins. This mechanism is versatile enough to drive resistance through efflux, drug modification, target modification, or even target bypass, depending on which gene gets amplified.23npj Antimicrobials and Resistance. Antibiotic resistance mediated by gene amplifications
Where the Search for New Targets Is Heading
The same five classical targets have underpinned antibiotic development for the better part of a century, and the pipeline of truly novel mechanisms is thin. Two emerging areas stand out as genuinely new ground.
The first is the outer membrane assembly machinery in Gram-negative bacteria. A protein complex called the Bam machine folds and inserts the barrel-shaped proteins that make up the outer membrane. Researchers have found peptidomimetic compounds that interact with key components of this complex, including BamA and LptD, selectively disrupting the outer membrane and killing the cell through a mechanism unlike anything on the current drug shelf.24PubMed Central. A Peptidomimetic Antibiotic Targets Outer Membrane Proteins and Disrupts Selectively the Outer Membrane in Escherichia coli Because this machinery is essential and exposed on the cell surface, it sidesteps some of the permeability problems that defeat many candidate drugs.
The second frontier is not about killing bacteria directly but about crippling their ability to adapt. The bacterial SOS response is a stress-activated repair system that kicks in when DNA is damaged, and it is one of the principal engines driving the evolution of resistance. When bacteria are exposed to antibiotics that damage DNA, the SOS pathway helps them survive and can accelerate the mutation rate, producing resistant offspring faster. Researchers have identified small molecules that block a key step in SOS activation, the self-cleavage of a regulatory protein called LexA. Genetic experiments show that shutting down the SOS response makes bacteria more sensitive to existing antibiotics and slows their acquisition of new resistance.25PubMed Central. Inhibitors of LexA Autoproteolysis and the Bacterial SOS Response Discovered by an Academic-Industry Partnership26PubMed. Nanobodies targeting LexA autocleavage disclose a novel suppression strategy of SOS-response pathway A drug like this would not replace antibiotics; it would extend their useful life by making it harder for bacteria to evolve their way out of trouble. The idea of pairing a conventional antibiotic with an anti-evolution adjuvant is still early-stage, but it represents a fundamentally different way of thinking about the resistance problem.